Pharmaceutical - AstraZeneca, Sanofi

Filter

Current filters:

AstraZenecaSanofi

Popular Filters

Ardelyx licenses NaP2b to Sanofi in deal worth up to $198 million

Ardelyx licenses NaP2b to Sanofi in deal worth up to $198 million

25-02-2014

US venture-funded biopharmaceutical company Ardelyx has licensed its novel phosphate transport NaP2b…

ArdelyxAstraZenecaLicensingNaP2bNephrology and HepatologyPharmaceuticalSanofitenapanor

BIO-Europe 2013: Nanotechnology innovation and the pharma industry

BIO-Europe 2013: Nanotechnology innovation and the pharma industry

20-11-2013

The future of nanotechnology in pharma has been discussed by the Nanomedicine panel at the BIO-Europe…

AstraZenecaEuropePharmaceuticalResearchSanofi

Morningstar analysts find GlaxoSmithKline has strongest pipeline

Morningstar analysts find GlaxoSmithKline has strongest pipeline

06-11-2013

Morningstar, an independent Chicago-based investment research firm, recently published the November 2013…

AbbVieAstraZenecaBayerFinancialGlaxoSmithKlineMerck & CoPharmaceuticalResearchSanofi

News briefs: AstraZeneca suspends share repurchasing; New CMO for Sanofi; Research facility for Octapharma

02-10-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) saw its shares dip 1.8% to £29.02 in early afternoon…

AstraZenecaFinancialManagementOctapharmaPharmaceuticalResearchSanofi

Amylin said to be attracting several Big Pharma suitors

16-05-2012

US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN), which earlier this year rebuffed a $22 per share…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbMerck & CoMergers & AcquisitionsPfizerPharmaceuticalRocheSanofiTakeda Pharmaceuticals

Xarelto and Brilinta already well represented in US hospital formularies

03-04-2012

In the USA, formulary inclusion of the new anticoagulant Xarelto (rivaroxaban) from German drug major…

AstraZenecaBayerBrilintaBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingNorth AmericaotamixabanPfizerPharmaceuticalSanofiXarelto

Back to top